ArticleBMC ophthalmology2025
Clinical profile of patients with retinal vein occlusion and its correlation with serum homocysteine levels.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pathophysiological Roles of Oxidative Stress and the Translational Potential of Antioxidant Therapy in Retinal Vein Occlusion.Antioxidants (Basel, Switzerland) · 2026Review
- Intravitreal Dexamethasone Implant in Retinal Vein Occlusion: A Pilot Study Exploring Baseline Ocular and Circulating Biomarkers.International journal of molecular sciences · 2026Article
- Modulating One-Carbon Metabolism with B-Vitamins to Protect the Retinal Barrier and Prevent Retinal Degeneration.Nutrients · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo study the clinical profile of patients diagnosed with retinal vein occlusion (RVO) and its correlation with serum Homocysteine (Hcy) levels.
methodsThis hospital-based cross-sectional study included all patients aged more than 18 years presenting to the Department of Ophthalmology from August 2024 to January 2025. A comprehensive ocular examination was done in all cases. Serum homocysteine levels (Hcy) were estimated in every case. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared in patients with and without hyperhomocysteinemia (HHcy) and varying severity of HHcy across diagnoses.
resultsThe study included 116 patients diagnosed with RVO. The mean age of patients was 56.4 ± 11.99 years. Most of the patients included in the study were males (60.3%). Central retinal vein occlusion (CRVO) was diagnosed in 32 (27.6%) eyes, and branch retinal vein occlusion (BRVO) in 84 (72.4%) eyes. HHcy was the most common modifiable risk factor in 63.8% of patients. Mild HHcy was seen in 58 (78.4%) and moderate HHcy in 16 (21.6%) patients. The mean Hcy levels in CRVO and BRVO were 19.34 ± 10.97 and 19.45 ± 11.1 µmol/L, respectively. There was a statistically insignificant difference in mean BCVA and CRT according to the presence or absence of HHcy and severity of HHcy across all diagnoses. Increasing age and history of stroke were positively associated with CRVO in univariate analysis.
conclusionElevated serum Hcy is associated with a majority of cases diagnosed with RVO. However, clinical presentation is not affected by the presence or absence of HHcy and its severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.